Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient

An antibody selected from the following [1] to [13]:

• [1] an antibody comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO:
• 14 as CDR1, the amino acid sequence of SEQ ID NO:
• 16 as CDR2, and the amino acid sequence of SEQ ID NO:
• 18 as CDR3;
• [2] an antibody comprising a light chain variable region having the amino acid sequence of SEQ ID NO:
• 20 as CDR1, the amino acid sequence of SEQ ID NO:
• 22 as CDR2, and the amino acid sequence of SEQ ID NO:
• 24 as CDR3;
• [3] an antibody comprising the heavy chain according to [1] and the light chain according to [2];
• [4] an antibody comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO:
• 26 as CDR1, the amino acid sequence of SEQ ID NO:
• 28 as CDR2, and the amino acid sequence of SEQ ID NO:
• 30 as CDR3;
• [5] an antibody comprising a light chain variable region having the amino acid sequence of SEQ ID NO:
• 32 as CDR1, the amino acid sequence of SEQ ID NO:
• 34 as CDR2, and the amino acid sequence of SEQ ID NO:
• 36 as CDR3;
• [6] an antibody comprising the heavy chain according to [4] and the light chain according to [5];
• [7] an antibody comprising a heavy chain variable region having the amino acid sequence of SEQ ID NO:
• 76 as CDR1, the amino acid sequence of SEQ ID NO:
• 77 as CDR2, and the amino acid sequence of SEQ ID NO:
• 78 as CDR3 (HE-39 Heavy chain);
• [8] an antibody comprising a light chain variable region having the amino acid sequence of SEQ ID NO:
• 79 as CDR1, the amino acid sequence of SEQ ID NO:
• 80 as CDR2, and the amino acid sequence of SEQ ID NO:
• 81 as CDR3 (HE-39 Light chain-1);
• [9] an antibody comprising a light chain variable region having the amino acid sequence of SEQ ID NO:
• 82 as CDR1, the amino acid sequence of SEQ ID NO:
• 83 as CDR2, and the amino acid sequence of SEQ ID NO:
• 84 as CDR3 (HE-39 Light chain-2);
• [10] an antibody comprising the heavy chain according to [7] and the light chain according to [8];
• [11] an antibody comprising the heavy chain according to [7] and the light chain according to [9];
• [12] an antibody having the activity equivalent to that of the antibody according to any of [1] to [11];
• and
• [13] an antibody that binds an epitope that is the same as the epitope bound by the antibody according to any of [1] to [12].

A method of producing a pharmaceutical composition comprising the steps of:

• (a) providing an anti-HB-EGF antibody;
• (b) determining whether the antibody of (a) has an internalizing activity;
• (c) selecting an antibody that has an internalizing activity;
• and
• (d) attaching a cytotoxic substance to the antibody selected in (c).